Prosensa names new supervisory board member
This article was originally published in Scrip
Dutch biopharmaceutical company Prosensa, which is developing therapies to treat rare diseases, has named Michael S Wyzga to its supervisory board – effective from its next meeting of shareholders on 17 June 2014. Mr Wyzga most recently served as president and chief executive officer of Radius Health. Prior to joining Radius, he was executive vice-president and chief financial officer of Genzyme (prior to its acquisition by Sanofi in April 2011). Mr Wyzga currently serves on the board of directors for OncoMed Pharmaceuticals, Akebia Therapeutics and Idenix Pharmaceuticals.